<DOC>
	<DOCNO>NCT00941967</DOCNO>
	<brief_summary>RATIONALE : Sorafenib tosylate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , gemcitabine hydrochloride oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether sorafenib tosylate effective give without gemcitabine hydrochloride oxaliplatin treat patient liver cancer . PURPOSE : This randomized phase II trial study sorafenib tosylate see well work give without gemcitabine hydrochloride oxaliplatin treat patient locally advance , unresectable , metastatic liver cancer .</brief_summary>
	<brief_title>Sorafenib Tosylate With Without Gemcitabine Hydrochloride Oxaliplatin Treating Patients With Locally Advanced , Unresectable , Metastatic Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess progression-free survival ( RECIST ) patient locally advance , unresectable metastatic hepatocellular carcinoma treat sorafenib tosylate v without gemcitabine hydrochloride oxaliplatin . Secondary - Evaluate tolerability regimens patient . - Determine objective response rate ( RECIST ) patient treat regimen . - Assess overall survival patient treat regimen . - Evaluate pharmacokinetics sorafenib tosylate . - Assess biomarkers ( e.g. , pERK level ) associate treatment response . - Assess angiogenic response functional imaging . OUTLINE : This multicenter study . Patients stratify accord performance status CLIP score . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral sorafenib tosylate arm I . Patients also receive gemcitabine hydrochloride IV 100 minute day 1 oxaliplatin IV 2 hour day 2 . Treatment gemcitabine hydrochloride oxaliplatin repeat every 14 day 12 course absence disease progression unacceptable toxicity . - Arm II : Patients receive oral sorafenib tosylate twice daily day 1-14 . In arm , course sorafenib tosylate repeat every 14 day absence disease progression unacceptable toxicity . Blood sample and/ tumor tissue sample may collect analysis . After completion study therapy , patient follow every 2 month disease progression every 6 month thereafter .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm hepatocellular carcinoma amenable liver transplantation Locally advance , unresectable , metastatic disease At least 1 lesion accurately measure ≥ 1 dimension accord RECIST criterion AND previously treat local therapy ( e.g. , intraarterial chemoembolization , radiofrequency ablation , percutaneous ethanol injection , cryoablation ) No presence bone metastasis No known brain metastasis PATIENT CHARACTERISTICS : WHO performance status 01 Life expectancy &gt; 12 week ANC &gt; 1,500/mm^3 WBC &gt; 3,000/mm^3 Platelet count ≥ 90,000/mm^3 Hemoglobin &gt; 10 g/dL Total protein ≥ 40 % ALT AST ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN Amylase lipase &lt; 1.5 time ULN Creatinine &lt; 1.5 time ULN Creatinine clearance ≥ 60 mL/min Albumin ≥ 2.8 mg/dL INR ≤ 2.3 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study 4 month females 6 month male completion study treatment CLIP score 03 No Child Pugh score B C cirrhosis No known HIV positivity No prior malignancy , except adequately treat curative basal cell skin cancer carcinoma situ cervix No known suspect allergy investigational agent agent give association study No cardiovascular disease , include follow : Cardiac arrhythmia require antiarrhythmic therapy , except betablockers digoxin chronic atrial fibrillation Active coronary artery disease ischemia Myocardial infarction within past 6 month NYHA class IIIV congestive heart failure No uncontrolled hypertension No severe active bacterial fungal infection &gt; CTCAE v3.0 grade 2 No peripheral neuropathy ≥ grade 2 No condition could affect absorption study drug , include follow : Malabsorption syndrome Disease significantly affect gastrointestinal function Bowel obstruction subobstruction No dysphagia inability swallow tablets No history seizures require longterm antiepileptic treatment No unstable condition would jeopardize safety compliance study include follow : Medical , psychological , social condition Substance abuse Legal incapacity limit legal capacity No psychological , familial , social , geographic reason would preclude clinical followup Must register social security program PRIOR CONCURRENT THERAPY : No prior organ transplantation immunosuppressive treatment No prior systemic chemotherapy systemic antiangiogenic treatment hepatocellular carcinoma No prior major resection stomach proximal small bowel Prior anticoagulation therapy ( e.g. , warfarin heparin ) allow INR parameter within normal limit range At least 4 week since prior local therapy lesion treat lesion may select target lesion No concurrent prior longterm treatment CYP3A4 inducer ( e.g. , rifampin , hypericum perforatum , phenytoin , carbamazepine , phenobarbital , dexamethasone ) No concurrent antitumoral treatment , include tamoxifen , interferon , somatostatin analogues No concurrent experimental drug anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
</DOC>